OAB is a chronic, potentially debilitating condition affecting a substantial proportion of patients in urologic practice, and effective long-term management depends on systematic escalation from behavioral modification through pharmacotherapy to third-line procedural options—including onabotulinumtoxinA (Botox)—when treatment objectives are not met.
Through a methodical, patient-driven evolution from 20 injection sites to a single posterior bladder wall injection, Steven Bernstein, MD, maintained onabotulinumtoxinA (Botox) efficacy—with a greater than 93% response rate and a mean retreatment interval of 7.5 months—while substantially improving patient comfort and persistence on therapy.
In more than 1000 onabotulinumtoxinA (Botox) treatments using a reduced-site protocol, Steven Bernstein, MD, observed a UTI rate of approximately 4.9% per treatment, a single clinically significant post-procedural bleed (early in experience with 20-site injection), and only 1 patient advised to undergo post-procedural catheterization—findings that support a streamlined, symptom-guided approach to complication management.
Proactive scheduling of the next onabotulinumtoxinA (Botox) treatment before the patient leaves the office—combined with a streamlined, reduced-site injection protocol—is a central strategy in Steven Bernstein, MD's practice for sustaining long-term persistence on therapy in patients with OAB.
Aleece Fosnight, MSPAS, PA-C, introduces her practice philosophy and credentials, characterizes the full scope of OAB's impact on patients who go undiagnosed or undertreated, and explains what the 2024 AUA/SUFU guideline's shift away from mandatory step therapy means for patient-centered care.
In this video, Aleece Fosnight, MSPAS, PA-C, reviews the evidence and practical application of behavioral interventions and pharmacologic therapy for OAB, including the clinical and safety rationale for leading with beta-3 agonists over anticholinergics, and outlines how she frames the transition to minimally invasive therapy for patients who have not responded to prior treatments.
Aleece Fosnight, MSPAS, PA-C, explains how she translates the guideline's Grade A evidence for sacral neuromodulation, posterior tibial nerve stimulation, and intradetrusor onabotulinumtoxinA into individualized treatment recommendations, and describes the shared decision-making process she uses when a patient is a candidate for all 3 options.
In this video, Aleece Fosnight, MSPAS, PA-C, provides a comprehensive review of intradetrusor onabotulinumtoxinA in OAB practice, covering preprocedural counseling, dose individualization including the evidence for escalation to 200 U in refractory patients, post-void residual evaluation, catheterization risk, and the systems-level strategies she uses to sustain long-term patient adherence to retreatment schedules.
Aleece Fosnight, MSPAS, PA-C, identifies the 3 most consequential gaps between the 2024 AUA/SUFU OAB guideline and real-world clinical practice—clinician awareness, prescribing mindset, and payer alignment—and offers her single most important takeaway for clinicians applying this framework at the point of care.
